Clinical trials: Genital Diseases, Male
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
This clinical trial was done to show whether a radioactive drug (I-131-1095) that binds to prostate-specific membrane antigen (PSMA) is useful in treating metastatic prostate cancer that is positive for PSMA.
- Conditions
- Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate
- Trial name
- ARROW (NCT03939689)
- Testing
- I-131-1095, Enzalutamide
- Where
- 27 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Prostatic Neoplasms
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
This study will assess different doses and regimens of radium-223 dichloride on the incidence of symptomatic skeletal events. Eligible subjects must have castration resistant prostate cancer with 2 or more skeletal metastases…
- Trial name
- NCT02023697
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 68 sites in United States, Australia and 13 more
- Volunteers
- 391 people
- Sponsor
- Bayer
Erectile Dysfunction
Evaluation of the Tissue Genesis Icellator Cell Isolation System to Treat Erectile Dysfunction
This clinical study is designed to investigate the safety and potential ability of relocated autologous SVF (stromal vascular fraction) to restore erectile function in men with ED (erectile dysfunction).
- Trial name
- NCT03518333
- Testing
- Injection of adipose derived cells into penis
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Tissue Genesis
Metastatic Castration-resistant Prostatic Neoplasms
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in…
- Trial name
- KLK2-comPAS (NCT07164443)
- Testing
- Pasritamig, Best Supportive Care (BSC), JNJ-87189401
- Where
- 174 sites in United States, Australia and 15 more
- Volunteers
- 1,203 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])
This is an open-label, nonrandomized, multicenter study conducted in two sequential parts: an initial Phase 2 Dose Optimization Period followed by the Phase 3 Diagnostic Performance Period.
- Trial name
- SPARROW (NCT07831824)
- Testing
- [68Ga]-LNTH-2401
- Where
- United States
- Volunteers
- 408 people
- Sponsor
- Lantheus Medical Imaging
Castration-Resistant Prostate Cancer (CRPC)
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit.
- Trial name
- NCT01534052
- Testing
- Enzalutamide
- Where
- 7 sites in United States, Moldova and 1 more
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Inc
Solid Tumor, Colorectal Cancer
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or…
- Conditions
- Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer
- Trial name
- NCT03872947
- Testing
- TRK-950, Irinotecan, Leucovorin
- Where
- 14 sites in United States, France
- Volunteers
- 138 people
- Sponsor
- Toray Industries, Inc
Vaginal Atrophy, Vulvovaginal Signs and Symptoms
Evaluation of the Efficacy and Safety of the Dermal Filler for Female Intimate Area Hydration and Atrophy of the Vagina.
The study is an open-label uncontrolled single-center study for the evaluation of the Performance characteristics (efficacy and safety) of the dermal filler "MMG-23-04-2019" on the female genital area for the medicinal…
- Conditions
- Vaginal Atrophy, Vulvovaginal Signs and Symptoms, Dyspareunia, Urinary Incontinence
- Trial name
- NCT04659668
- Testing
- MMG-23-04-2019
- Where
- Bulgaria
- Volunteers
- 37 people
- Sponsor
- Mesoestetic Pharma Group S.L.
Prostate Cancer
GP Extended Action Triptorelin
The purpose of this study is to demonstrate that treatment with a 6-monthly injection of hormone therapy is as good and as well tolerated as the standard 3-monthly hormone therapy injections available for treating prostate…
- Trial name
- GREAT (NCT01673984)
- Testing
- Decapeptyl® SR 22.5mg, Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg
- Where
- 35 sites in United Kingdom
- Volunteers
- 27 people
- Sponsor
- Ipsen
Human Immunodeficiency Virus (HIV)
SPL7013 Gel - Male Tolerance Study
The purpose of this study is to determine if SPL7013 Gel (VivaGel™) is safe when applied topically once a day for seven consecutive days to the shaft and glans of the penis in healthy male volunteers.
- Trial name
- NCT00370357
- Testing
- 3% w/w SPL7013 Gel (VivaGel™)
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Starpharma Pty Ltd
Prostate Cancer
Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer
The purpose of this study is to look at the efficacy and safety of leuprolide acetate in patients with prostate cancer.
- Trial name
- NCT00128531
- Testing
- leuprolide acetate
- Where
- 28 sites in United States, Austria and 7 more
- Volunteers
- 120 people
- Sponsor
- GP-Pharm
Prostate Cancer
High-Intensity Focused Ultrasound in Treating Patients With Locally Recurrent Prostate Cancer
RATIONALE: Highly focused ultrasound energy may be able to kill cancer cells by heating the tumor without affecting the surrounding tissue.
- Trial name
- NCT00030277
- Testing
- high-intensity focused ultrasound ablation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Focus Surgery
mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
- Trial name
- P300 (NCT06785636)
- Testing
- Pocenbrodib, Pocenbrodib and Darolutamide
- Where
- 19 sites in United States
- Volunteers
- 120 people
- Sponsor
- Pathos AI, Inc.
Prostatic Hyperplasia
Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)
The purpose of this study is to determine if transurethral photodynamic therapy with lemuteporfin has a therapeutic effect on lower urinary tract symptoms due to an enlarged prostate.
- Trial name
- NCT00116571
- Testing
- Lemuteporfin for injection, Transurethral drug delivery system, Transurethral light delivery system
- Where
- 9 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- QLT Inc.
Prostate Cancer
An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer
This trial is an open-label, multi-centre, single arm extension for the 000006 trial in Chinese patients with prostate cancer. Eligible patients will receive monthly (28-day intervals) maintenance doses of 80 mg (20 mg/mL)…
- Trial name
- PandaExtension (NCT02015871)
- Testing
- Degarelix
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Ferring Pharmaceuticals
Premature Ejaculation
Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE)
This is a Phase 2a, double-blind, placebo-controlled, crossover study evaluating the efficacy, safety, and patient-reported outcomes of KH-001 in men with lifelong premature ejaculation (LPE).
- Trial name
- NCT07434271
- Testing
- KH-001 ODT
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Kadence Bio
Prostate Cancer
Water Vapor Ablation for Grade Group 3 Prostate Cancer
The goal of this study is to evaluate the safety and effectiveness of the Vanquish Water Vapor Ablation System ("Vanquish") in participants with Grade Group 3 (GG3) intermediate-risk prostate cancer.
- Trial name
- VAPOR 3 (NCT07652164)
- Testing
- Water Vapor Ablation
- Volunteers
- 120 people
- Sponsor
- Francis Medical Inc.
Prostatic Hyperplasia
Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS
This study was designed to assess the effectiveness of dutasteride in the actual clinical practice of prostate assessment clinics in the UK in accordance with best practice over a 12-month period.
- Trial name
- NCT00316732
- Testing
- IPSS Questionnaire, EQ-5D Questionnaire
- Where
- 27 sites in United Kingdom
- Volunteers
- 173 people
- Sponsor
- GlaxoSmithKline
Erectile Dysfunction
Safety and Efficacy of Bi-Polar Radiofrequency for the Treatment of Erectile Dysfunction
The goal of this prospective pilot study is to learn about the Safety and Efficacy of Radiofrequency (RF) for the Treatment of Erectile Dysfunction.
- Trial name
- NCT06299332
- Testing
- Device treatment
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- InMode MD Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.